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Background: Venous thromboembolism (VTE) is a common preventable cause of mortality in hospitalized medical
patients. Despite rigorous randomized trials generating strong recommendations for anticoagulant use to prevent
VTE, nearly 40% of medical patients receive inappropriate thromboprophylaxis. Knowledge-translation strategies are
needed to bridge this gap.
Methods: We conducted a 16-week pilot cluster randomized controlled trial (RCT) to determine the proportion of
medical patients that were appropriately managed for thromboprophylaxis (according to the American College of
Chest Physician guidelines) within 24 hours of admission, through the use of a multicomponent knowledge-
translation intervention. Our primary goal was to determine the feasibility of conducting this study on a larger scale.
The intervention comprised clinician education, a paper-based VTE risk assessment algorithm, printed physicians’
orders, and audit and feedback sessions. Medical wards at six hospitals (representing clusters) in Ontario, Canada
were included; three were randomized to the multicomponent intervention and three to usual care (i.e., no active
strategies for thromboprophylaxis in place). Blinding was not used.
Results: A total of 2,611 patients (1,154 in the intervention and 1,457 in the control group) were eligible and
included in the analysis. This multicomponent intervention did not lead to a significant difference in appropriate
VTE prophylaxis rates between intervention and control hospitals (appropriate management rate odds ratio = 0.80;
95% confidence interval: 0.50, 1.28; p = 0.36; intra-class correlation coefficient: 0.022), and thus was not considered
feasible. Major barriers to effective knowledge translation were poor attendance by clinical staff at education and
feedback sessions, difficulty locating preprinted orders, and lack of involvement by clinical and administrative
leaders. We identified several factors that may increase uptake of a VTE prophylaxis strategy, including local
champions, support from clinical and administrative leaders, mandatory use, and a simple, clinically relevant risk
assessment tool.
Conclusions: Hospitals allocated to our multicomponent intervention did not have a higher rate of medical
inpatients appropriately managed for thromboprophylaxis than did hospitals that were not allocated to this
strategy.
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Venous thromboembolism (VTE) is a common prevent-
able cause of mortality in hospitalized patients [1-3]. Ap-
proximately 60% of symptomatic VTE occurs in medical
patients, and recent hospitalization for medical illness
accounts for 25% of all community-diagnosed VTE [1-3].
Not surprisingly, multiple agencies have identified throm-
boprophylaxis as a patient safety priority [4,5], and it has
become a key requirement for hospital accreditation [6-8].
Thromboprophylaxis has been shown in multiple well-
designed trials to be effective, safe, cost-saving, and easy
to administer [9]. Despite these compelling considerations,
nearly 40% of at-risk medical patients receive inappropri-
ate thromboprophylaxis [10-14].
Prior knowledge-translation (KT) interventions using
“high-tech” strategies, such as electronic alerts, compu-
terized decision support systems, and computerized
order entry, have improved prophylaxis rates [15-18].
One study of 2,506 hospitalized patients showed that
electronic alerts reduced the risk of VTE by 41% after 90
days [17]. The results of these studies are encouraging
but are not applicable to hospitals without the required
computer infrastructure. A single-center “low-tech” study,
with potentially more generalizable results, used education
sessions, a paper-based decision support tool, and audit
and feedback sessions in hospitalized medical and surgical
patients [19]. This intervention increased the proportion
of at-risk patients who received thromboprophylaxis from
58% to 93% over three years. The single-center BEHAVE
study found that multidisciplinary education sessions, ver-
bal reminders, daily charting of prophylaxis, and weekly
feedback to individual physicians increased the median
patient-days of thromboprophylaxis from 60 to 91 days in
a medical-surgical intensive care unit [20]. While the
impact of these low-tech interventions is also promis-
ing, understanding whether their impact is generalizable
requires evaluation in diverse hospital settings with
medical patients who are at greatest risk of inappropri-
ate thromboprophylaxis.
To lay the groundwork for our trial, we conducted
questionnaires and interviews of healthcare providers to
assess perceptions about the importance of thrombo-
prophylaxis, barriers to optimizing prophylaxis, and the
potential success and feasibility of interventions to
optimize prophylaxis [21,22]. While perceived as im-
portant, not all healthcare providers recognized that
thromboprophylaxis was underused in medical patients.
Our pilot studies suggested that a potentially successful
and feasible intervention would be comprehensive and
would be comprised of healthcare provider education,
screening and risk-stratifying all patients, and pre-
printed orders. This concept was supported by pub-
lished systematic reviews [23-25] and thus, we created a
KT intervention that included these components.The Strategies to Enhance Venous Thromboembolism
Prophylaxis in Hospitalized Medical Patients (SENTRY)
pilot trial was designed to determine if a low-tech
paper-based strategy could be feasibly implemented and
if it could improve appropriate thromboprophylaxis
in hospitalized medical patients. Appropriate and in-
appropriate thromboprophylaxis were defined a priori
according to the criteria outlined in Table 1. Further-
more, to be deemed “appropriate”, we required the
correct administration or the correct nonadministration
of thromboprophylaxis (as per the American College of
Chest Physicians [ACCP] guidelines) to occur within 24
hours of admission to the internal medicine service. The
primary objective was to determine the feasibility of
implementing the multicomponent SENTRY interven-
tion. We also sought to determine if hospitals allocated to
our intervention had a higher proportion of hospitalized
medical patients appropriately managed for thrombopro-
phylaxis within 24 hours of admission than hospitals not
allocated to this strategy and if it minimized errors of
commission (i.e., administering prophylaxis when un-
necessary) and errors of omission (i.e., not administering
prophylaxis when necessary).Methods
This study received approval from the Institutional
Research Ethics Board at each participating site. As the
study involved a minimal/low-risk intervention, each
Board determined that it could be conducted without
informed consent from patients or surrogates.Setting and participants
SENTRY was a 16-week cluster randomized controlled
trial (RCT) conducted in the medical wards of six hospi-
tals in Ontario, Canada from January to April 2009.
Hospitals were the unit of randomization, and each
hospital represented a cluster. Eligible hospitals were
chosen based on geographic convenience, the availabil-
ity of a physician willing to serve as the local principal
investigator, and the lack of a formal institutional strat-
egy to improve thromboprophylaxis. To ensure balance
between the intervention and control groups, we used a
stratified randomization strategy, based on the Ontario
Ministry of Health and Longterm Care’s Group A/B/C
classification of hospitals. Each group included one hos-
pital from Group A (academic hospitals), one hospital
from Group B (community hospitals having greater than
100 beds), and one hospital from Group C (community
hospitals having fewer than 100 beds). Both Group A
hospitals had a consultative thromboembolism service.
None of the hospitals used medical patient admission
order sets. Randomization of clusters, using a random
number table, was concealed, with a 1:1 allocation
Table 1 Definition of appropriate thromboprophylaxis






Did the patient have
thrombosis risk factors?a
YES – and bleeding
risk factorb
Error of commission Appropriate prophylaxis
(appropriate receipt)
Error of omission




Error of omission Error of omission
NO Error of commission Error of commission Appropriate prophylaxis
(appropriate nonreceipt)
aThrombosis risk factors: congestive heart failure, chronic obstructive pulmonary disease, interstitial lung disease, acute ischemic stroke, active cancer, sepsis,
acute neurological disease, inflammatory bowel disease, prior venous thromboembolism. bBleeding risk factors: acute bleed, at risk for bleeding, recent bleed,
coagulopathy, thrombocytopenia.
Pai et al. Implementation Science 2013, 8:1 Page 3 of 11
http://www.implementationscience.com/content/8/1/1sequence within strata. The allocation sequence was
generated by the study statistician.
We enrolled all patients ≥18 years of age admitted to
the service of general internal medicine during the study
period. Patients admitted under cardiology, intensive
care, or other medical subspecialties were not included.
Patients were excluded if they were receiving therapeutic
anticoagulation or had a length of stay less than 24Figure 1 Standardized VTE risk assessment and physician order form
thromboembolism, COPD = chronic obstructive pulmonary disease, ILD =
system, INR = international normalized ratio, aPTT = activated partial thromhours. For patients admitted more than once, only the
first admission was included. Data on age, sex, admission
diagnosis, length of stay, risk factors for thrombosis, risk
factors for bleeding, the use of mechanical prophylaxis
(intermittent pneumatic compression devices or anti-
embolic stockings), and anticoagulant prophylaxis (unfrac-
tionated or low-molecular-weight heparin) were recorded
from the hospital chart, using a standardized data. Legend: ACCP = American College of Chest Physicians, VTE = venous
interstitial lung disease, GI = gastrointestinal, CNS = central nervous
boplastin time.
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sumption that if prophylaxis was ordered in the hospital
chart, it was actually received by the patient.
Intervention
This study was not blinded. Medical wards in the con-
trol group received “usual care”, which we defined as
having no active or passive KT strategies to improve
thromboprophylaxis in place. Medical wards in the inter-
vention group received a multicomponent intervention
consisting of the following:
1. Education sessions: Distribution of posters; a
pamphlet describing current VTE practice patterns
and the need to optimize thromboprophylaxis; and
bimonthly educational sessions for ward physicians
(and house staff, if applicable), nurses, and
pharmacists. Pamphlets were distributed in paper
format and via electronic mail to individuals who
could not attend the sessions.
2. Standardized VTE risk assessment algorithm and
physicians’ orders: (see Figure 1) These paper-based
forms, modeled after the 8th edition of the ACCP
Evidence-Based Clinical Practice Guidelines, were
available on internal medicine wards during the study
period [4]. Local principal investigators (PIs) were
asked to ensure that clinical staff were aware of the
forms and to encourage their completion for eligible
patients.
3. Audit and feedback: Real-time chart audits of eligible
patients were done to determine whether patients
were appropriately managed for thromboprophylaxis
within 24 hours of admission. The entire health
record during the relevant admission was searched to
corroborate thrombosis and bleeding risk factors. All
audits were done by one of two data management
assistants, and data entry was validated by the study
coordinator (NL) and two research assistants.
Performance-based feedback sessions were done at 4,
12, and 16 weeks to relay results to clinical staff.
Aggregate feedback was provided verbally and in a
written handout at the sessions. The handout was
also distributed in paper format and via electronic mail
to individuals who could not attend the sessions.
Outcomes
We defined the primary study outcome—feasibility—a
priori according to the proportion of eligible medical
patients who received appropriate prophylaxis, based
on the criteria shown in Table 1. The intervention
was considered definitely feasible, possibly feasible, or
not feasible if the difference in the proportion of at-
risk patients receiving appropriate prophylaxis in the
intervention hospitals versus the usual care hospitalswas >25%, 10–25%, and <10%, respectively. The sec-
ondary outcomes of this study were as follows:
1. The percentage of patients appropriately managed
for thromboprophylaxis within 24 hours of admission
to the internal medicine service (i.e., administering
prophylaxis when necessary, and not administering
prophylaxis when unnecessary, as per the ACCP
guidelines)
2. The percentage of patients subject to errors of
commission within 24 hours of admission to the
internal medicine service (i.e., administering
prophylaxis when unnecessary as per the ACCP
guidelines)
3. The percentage of patients subject to errors of
omission within 24 hours of admission to the
internal medicine service (i.e., not administering
prophylaxis when necessary as per the ACCP
guidelines)
The recommendations of the 8th ACCP Evidence-Based
Clinical Practice Guidelines on Antithrombotic Therapy
were used to determine if prophylaxis was appropriate or
not. As per the guidelines, thromboprophylaxis is indicated
for patients with congestive heart failure, acute respiratory
disease, and immobility plus one or more additional risk
factors for VTE (acute ischemic stroke, active cancer, sep-
sis, acute neurologic disease, inflammatory bowel disease,
previous VTE, or thrombophilia). Patients were considered
to be immobile if there was a physician order for bed rest
or if chart notes indicated the patient could not ambulate
without support. Recommended pharmacologic prophy-
laxis regimens include low-dose unfractionated heparin
(UFH) (5000 U twice daily or thrice daily) or low-
molecular-weight heparin (LMWH) at manufacturers’ sug-
gested prophylactic doses. Recommended mechanical
prophylaxis options include elastic stockings or intermit-
tent pneumatic compression devices. The “receipt of ap-
propriate thromboprophylaxis” was defined as a physician’s
order for the correct type and dose of thromboprophylaxis
prescribed within the first 24 hours of admission, taking
into account the individual patient’s thrombosis and bleed-
ing risks. The rate of compliance, the duration of prophy-
laxis, and thromboprophylaxis indications after 24 hours
were not examined in this study.
We captured qualitative data on the ease of form
implementation and use via formal feedback sessions, as
well as paper and electronic questionnaires distributed
to healthcare providers at the intervention hospitals at
the end of the study.
The primary goal of this pilot trial was to assess the
feasibility of implementing the SENTRY intervention.
Therefore, the sample size was primarily based on feasi-
bility considerations, not the trial’s secondary outcomes
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and errors of commission) [26,27]. To achieve “definite
feasibility”, we specified that the baseline proportion of
61% of patients appropriately managed for thrombopro-
phylaxis in the control group (a figure based on previous
studies conducted at our institution) would have to in-
crease to 76.25% in the intervention group (Lloyd NS,
Douketis JD, Cheng J, Moinuddin I, Pai M, Thabane L,
Cook DJ, Schunemann HJ, Spencer FA, Haynes RB: Anti-
coagulant prophylaxis against venous thromboembolism
in hospitalized medical patients: an assessment of current
practices and determinants of appropriate and inappro-
priate prophylaxis management, unpublished) (i.e., a 25%
relative increase from 61%). To estimate the difference in
rates of appropriate thromboprophylaxis between groups
with a 95% confidence interval (CI) and a margin of error
of 0.05, we estimated that 644 patients were needed per
group. Thus, our goal was to recruit a total of 1,290
patients, with at least 645 in each group. As this was a
pilot trial, the goal was to generate crude estimates of
feasibility and data to calculate an intraclass correlation
coefficient (ICC) for use in future studies. Thus, the sam-
ple size in SENTRY was not adjusted for clustering.
Statistical analysis
Patient and cluster demographics are reported using de-
scriptive statistics. The feasibility outcomes are reported as
percentages. The rates of appropriate thromboprophylaxis
in the intervention and control group were comparedFigure 2 Flow of clusters and participants through SENTRY trial.using an odds ratio (OR) with an associated 95% CI.
Results were considered statistically significant at alpha =
0.05 (two-sided p value). Observations within each partici-
pating hospital were assumed more likely to be similar
than observations between participating hospitals. A logis-
tic model using the generalized estimating equation (GEE)
method was used to account for this clustering effect, in-
corporating both within-hospital and between-hospital var-
iations. An ICC and variance inflation factor (VIF) were
also calculated to assess the impact of the clustering effect
[28]. When VIF is >2, the impact of the clustering effect is
considered to be large. Quantitative analyses were con-
ducted using SAS 9.3 (SAS Institute Inc., Cary, NC). Quali-
tative data were summarized in duplicate by two
individuals (MP and NL), and comments were grouped
into thematic areas.
Results
Six Ontario hospitals participated in the SENTRY study
(see Figure 2). A total of 3,527 medical patient charts
were reviewed during the 16-week study period; 2,611
patients (1,154 intervention, 1,457 control) were eligible
and included in the analysis. The remaining 916 patients
were excluded because they were <18 years of age and/
or receiving therapeutic anticoagulation at the time of
admission and/or had already been included in the study
during a previous admission. Table 2 outlines the demo-
graphic characteristics of eligible patients, while Table 3
outlines the demographic characteristics of eligible
Pai et al. Implementation Science 2013, 8:1 Page 6 of 11
http://www.implementationscience.com/content/8/1/1clusters. The intervention and control groups were com-
parable. However, some baseline differences were noted.
Specifically, there was a higher prevalence of acute re-
spiratory disease (16% versus 9%) and sepsis (13% versus
8%) in the intervention group, and a higher prevalence
of cancer in the control group (12% versus 8%). There
was a higher prevalence of patients at risk for bleeding
in the intervention group (10% versus 6%), as well as a
higher prevalence of patients at risk for VTE without
risk of bleeding (38% versus 32%). Clusters were com-
parable for baseline characteristics. Table 4 outlines the
prophylaxis options prescribed in the intervention and
control group hospitals.
The VTE risk profiles of patients at intervention and
control hospitals were comparable (see Tables 2, 3). At
the end of the trial, 64.5% (744/1,154) of patients in
the intervention group and 66.6% (970/1,457) of
patients in the control group were appropriately mana-
ged for thromboprophylaxis within 24 hours of admis-
sion. After adjusting for within-hospital correlation,
there was no significant difference between the rates
of appropriate thromboprophylaxis between groups
(OR = 0.80 in intervention versus control group; 95%Table 2 Patient characteristics
Age (y): Median (min, max)
Male: n (%)
Length of stay (days): Median (min, max)










Bleeding risk factors: n (%)
Acute bleeding




VTE risk profile: n (%)
At risk for VTE without risk of bleeding
At risk for VTE with risk of bleeding
Not at risk for VTE
All percentages use total number of eligible patients as denominator.
VTE = venous thromboembolism.CI: 0.50, 1.28; p = 0.36 after adjustment for cluster-
ing effect; ICC = 0.022; VIF = 10.55; see Table 5). The
rates of errors of commission and errors of omission
were not significantly different between groups. (Errors
of omission: OR = 1.30 in intervention versus control
group; 95% CI: 0.68, 2.50; p = 0.43, after adjusting for
clustering effect. Errors of commission: OR = 1.01 in
intervention versus control group; 95% CI: 0.43, 2.37;
p = 0.97, after adjusting for clustering effect.) The
intervention did not achieve the prespecified target of
definite feasibility, defined as a rate of appropriate
thromboprophylaxis of 76% in the intervention group.
Feedback was received from 39 completed question-
naires (21 physicians, 10 nurses, 8 pharmacists) out of
over 100 questionnaires distributed to healthcare provi-
ders at the intervention hospitals. Feedback was also
received via the formal feedback sessions. Four themes
were identified: order form accessibility, order form con-
tent, factors that reinforced appropriate prophylaxis, and
the reason why inappropriate prophylaxis rates remained
high. Physicians stated that forms were sometimes in-
accessible and that forms needed to be available in the
emergency department, where patients were generallyIntervention group Control group
(total n = 1154) (total n = 1457)
72 (18,100) 72 (18,102)
534 (46) 688 (47)
4 (0,79) 5 (0,133)
140 (12) 166 (11)
181 (16) 133 (9)
68 (6) 92 (6)
93 (8) 172 (12)
145 (13) 111 (8)
24 (2) 13 (1)
23 (2) 25 (2)
26 (2) 22 (2)
637 (55) 806 (55)
64 (6) 134 (9)
116 (10) 90 (6)
22 (2) 5 (0)
93 (8) 185 (13)
36 (3) 50 (3)
436 (38) 465 (32)
132 (11) 167 (11)
586 (51) 825 (57)
Table 3 Cluster characteristics
Intervention group Control group
(total n = 3) (total n = 3)
Number of eligible patients per cluster: Mean (min, max) 460 (367, 616) 375 (238, 510)
Number of hospitals with a consultative thromboembolism service 1 1
Geographic area Southern Ontario Southern Ontario
Number of hospitals in Ontario Ministry of Health and Longterm Care Hospital Class:
Class A (academic hospitals) 1 1
Class B (community hospitals, >100 beds) 1 1
Class C (community hospitals, <100 beds) 1 1
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they often forgot to put the form on patients’ charts or
prompt physicians to use it. They attributed this to
many other forms competing for their attention. Many
respondents suggested that if the forms were automatic-
ally placed on every chart as part of a standard
admission protocol, uptake would be improved. The
content of the form received mixed reviews, and
many physicians emphasized that the ACCP guidelines
(which formed the basis of the risk assessment algo-
rithm) were not “one size fits all.” They stated that gen-
eral medical patients frequently presented exceptions to
the rules in the risk assessment algorithm. Respondents
also stated that some of the terms in the algorithm, such
as “immobility” and “sepsis”, needed to be more clearly
defined. Participants reported that educational sessions
reinforced their use of appropriate prophylaxis, though
their busy schedules and lack of protected educational
time made it difficult to attend these sessions. They
also suggested that negative reinforcement, such as
practitioner-specific report cards citing specific errors,
might be more effective than reporting aggregate data.
Finally, when asked why inappropriate prophylaxis rates
remained high, each group of healthcare professionals—
physicians, nurses, and pharmacists—considered the
other groups to be responsible for the inappropriate
management. They expressed that their own workload
was too heavy to take on additional primary responsibility
for thromboprophylaxis and that other groups should take
more ownership of the problem.Table 4 Prophylaxis ordered in intervention and control grou
Pat
No prophylaxis
Unfractionated heparin at suggested prophylaxis dose
Low-molecular-weight heparin at suggested prophylaxis
dose
Anti-embolic stockings
Intermittent pneumatic compression devicesDiscussion
Hospitals that were allocated to receive our multicompo-
nent intervention comprising education, standardized
paper-based physician orders, and group audit and feed-
back did not have a higher rate of hospitalized medical
patients appropriately managed for thromboprophylaxis
within 24 hours of admission than did hospitals that
were not allocated to this strategy (63% vs. 67%). This
finding, coupled with the problems associated with en-
suring preprinted orders were placed in all medical
charts, led us to conclude that this intervention should
not be provided on a larger scale without major revision
and testing. That is, it was not feasible. The study was
primarily designed to assess the feasibility of a future
large cluster randomized trial. It was conducted in a
broad spectrum of university and community-based hos-
pital settings. Thus, the feasibility assessments and
results are generalizable to similar settings.
Several observations may explain our findings. First,
despite our efforts to encourage the use of the thrombo-
prophylaxis forms for every admitted patient, staff stated
that they often forgot to use them, as they were over-
whelmed by the many other forms in circulation on the
wards. This suggests that for an order set to be successful,
it may have to be embedded within a mandatory, widely
available patient admission package. Giving healthcare
providers an opportunity to opt out or overlook an order
set can result in poor compliance. Second, though the
SENTRY order set was modeled on the widely accepted
ACCP guidelines for thromboprophylaxis, clinicians statedps
ients in intervention group
receiving












Odds ratio (95% confidence interval),
p value
Number of patient charts reviewed 1573 1954
Eligible patients 1154 (73) 1457 (75)
Received appropriate prophylaxis strategy 744 (64) 970 (67) 0.80 (0.50, 1.28), p = 0.36
Appropriate receipt of prophylaxis 263 (23) 290 (20) 1.09 (0.39, 3.11), p = 0.86
Appropriate nonreceipt of prophylaxis 481 (42) 680 (47) 0.76 (0.40, 1.44), p = 0.40
Received inappropriate prophylaxis strategy 410 (33) 487 (33) 1.25 (0.78, 1.99), p = 0.36
Error of commission (inappropriate receipt of
prophylaxis)
105 (9) 145 (10) 1.01 (0.43, 2.37), p = 0.97
Error of omission (inappropriate nonreceipt of
prophylaxis)
305 (26) 342 (23) 1.30 (0.68, 2.50), p = 0.43
All percentages use total number of eligible patients as denominator. All odds ratios compare the specified group to all other eligible patients.
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ical situation. Thromboprophylaxis guidelines for general
medical patients are clearly not universally accepted. The
ACCP guidelines are all “strong” recommendations, based
on high-quality evidence (RCTs without important limita-
tions or strong evidence from observational studies) [29].
However, hospitalized medical patients are complex and
heterogeneous. “One size fits all” guidelines may not
translate well to this patient population, and the clinical
gestalt may play an important role in risk stratification. As
suggested by the ACCP guideline authors themselves, the
feasibility, usability, practicality, and applicability of even
well-supported recommendations may differ in specific
subgroups of patients [30]. Clinicians may rightly refrain
from implementing thromboprophylaxis guidelines in cer-
tain patients, based on their specific characteristics. Thus,
an important process measure to consider in future stud-
ies would be whether thromboprophylaxis was considered
in every patient, not just if it followed the guidelines. Fi-
nally, despite efforts to engage all members of the health-
care team, there was a lack of awareness of the SENTRY
trial in the intervention hospitals during its conduct. (By
design, awareness was not measured in the control hospi-
tals where practice was unchanged.) Busy clinical sche-
dules and “information overload” prevented staff from
attending educational sessions and reviewing posters and
leaflets. There was also a lack of involvement of clinical
and administrative leaders, resulting in the absence of a
sustained internal push to improve practice. Recruiting a
single local PI at each intervention site did not promote
the use of the standardized forms and consideration of
thromboprophylaxis in every patient. This intervention
may have been more successful had there been buy-in and
promotion of this patient safety initiative by the majority
of staff physicians on the medical service.
When compared to the impact of other KT studies of
thromboprophylaxis, the lack of comparable success
achieved by SENTRY can be explained by two additionalconsiderations. All prior low-tech studies (and all prior
high-tech studies apart from Galanter et al.) were con-
ducted at a single center. Our trial was unique, as we
implemented our intervention in several centers across
the province, to assess its generalizability. However,
when we attempted to “scale up” our KT intervention,
the increased demand on time and resources proved to
be challenging. Previous single-center studies examined
geographically contained systems [15,17-20]. It may be
easier to effect change in these closed systems, as there
is a concentration of resources, a single target audience,
and recognized opinion leaders. In addition, many of the
most successful studies incorporated high-tech elements,
such as computerized decision support systems (CDSS)
and electronic alerts [15-18]. Our region, like many
others, does not have the resources or infrastructure to
adopt high-tech CDSSs or electronic alerts. There is
widespread enthusiasm for CDSSs in part because it is
perceived that they require less clinical decision making
than order sets and can guide healthcare providers to-
wards evidence-based practices. Though there is some
evidence that CDSSs can improve practitioner perform-
ance, further research is needed to determine their
effect on patient-important outcomes and their cost-
effectiveness [31].
Our study has several potential limitations that may
have impacted the feasibility of the intervention. First, as
many patients are admitted to the medical service from
the emergency department, we recognize that uptake of
the forms may have increased had they been available in
the ER as well, instead of solely on the medical wards.
Future studies require intervention at all points of entry
to the inpatient service. Second, though all information
was audited from patients’ charts, some variables (e.g.,
immobility) were ambiguously defined and inconsistently
documented by healthcare providers. This may have
resulted in an incomplete picture of patients’ thrombosis
and bleeding risks. Third, physicians in this study rarely
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scribed or omitted prophylaxis. Study participants told
us that they often used clinical judgment as an adjunct
to guidelines when prescribing thromboprophylaxis, but
the lack of documentation did not allow us to fully ex-
plore the impact of clinical judgment on prescribing
practices. Fourth, the house staff at the two academic
centers in the study may have been a source of contam-
ination. Additional house staff occasionally provided
overnight coverage at the intervention group academic
center. These additional house staff were not formally
educated about the study, so they effectively functioned
as if they were in the control group. Conversely, add-
itional house staff who provided overnight coverage at
the control group academic center may have been previ-
ously educated about our study while working at the
intervention group academic center. Thus, they effect-
ively functioned as if they were in the intervention
group. The resulting bias is somewhat offset by the fact
that staff physicians did not rotate between sites and that
their clinical judgment ultimately guided patient care.
Fifth, the strength of our study is compromised by the
lack of data on fidelity in the intervention group (i.e.,
the extent to which the intervention components were
used/received as intended). For example, we did not for-
mally collect data on the level of uptake of the forms at
each site, or the attendance rates at the educational ses-
sions. These data would have allowed us to more thor-
oughly investigate the feasibility of the KT intervention
and monitor for potential contamination. Sixth, our
study was not designed to measure safety and efficacy
outcomes of thromboprophylaxis, such as thrombosis,
heparin-induced thrombocytopenia, or major bleeding.
Seventh, we did not measure baseline data on appropri-
ate thromboprophylaxis rates at each hospital prior to
implementing the intervention. Instead, we used previ-
ously reported rates. Had we obtained baseline rates
from the study sites, we may have seen a significant dif-
ference in the secondary outcomes, as we would have
been comparing improvement within each site. Eighth, it
is possible that baseline differences in the intervention
and control groups reduced the feasibility of our inter-
vention. There was a higher prevalence of patients at
risk for VTE (without risk of bleeding) in the interven-
tion group. Though the preprinted orders accounted for
patients with a spectrum of bleeding and thrombotic
risks, it is possible that clinicians in the intervention
hospitals were not comfortable applying an algorithmic
VTE prophylaxis approach to "sicker" patients (though
their illnesses contributed to an increased risk of VTE).
Finally, we did not adjust the sample size in this study
for clustering. This was intentional; SENTRY, like other
pilot trials, was designed to generate crude estimates of
intervention feasibility and sufficient data to calculate anICC for use in future studies. Analysis of the secondary
outcomes was exploratory and should be judged on the
basis of feasibility results.
The strengths of our study include participation of both
academic and community hospitals, screening of all con-
secutive medical admissions during the study period, and
the use of a standardized KT intervention and data collec-
tion form. We also used rigorous operational definitions to
determine whether each patient’s thromboprophylaxis man-
agement was “appropriate”. Though many previous studies
have reported rates of thromboprophylaxis, we went be-
yond this outcome, and aimed to determine whether
prophylaxis was appropriate or not using the widely
accepted 8th ACCP Evidence-Based Clinical Practice Guide-
lines on Antithrombotic Therapy. This a priori decision to
consider not only omission or commission of prophylaxis,
but to consider evidence-based management as well, is an-
other strength of our study. Finally, acknowledging that
quantitative outcomes are insufficient to explain why an
intervention is successful or not, we also captured qualita-
tive data to elaborate on the impact of our intervention.
The key lesson learned from this study was that a KT
intervention that relies on the voluntary cooperation of
front-line clinicians (i.e., a bottom-up approach) was not
feasible, and thus insufficient to effect change in thrombo-
prophylaxis patterns. While we still advocate a front-line
team approach to thromboprophylaxis, a top-down push
from clinical and administrative leaders may also be neces-
sary [32-34]. Although our prior qualitative study did not
support the contention that quality improvement is a
shared responsibility among different clinician groups [21],
accreditation standards today are such that both clinicians
and managers are responsible for patient safety. Thus, clear
support for thromboprophylaxis at the level of the
healthcare organization may address some very specific
modifiable barriers to change identified by SENTRY
participants, including the lack of protected time for
team members to participate in education and the
nonmandatory use of quality improvement resources.
At the healthcare system level, the consideration of
thromboprophylaxis appropriate to the individual pa-
tient as a performance measure, tied to healthcare ac-
creditation and remuneration, may also cultivate a
culture of patient safety, reinforce evidence-based prac-
tice, and reward centers for positive results. This study
identified several factors that may increase uptake of a
VTE prophylaxis strategy, including local champions, sup-
port from clinical and administrative leaders, mandatory
use, and a simple, clinically relevant risk assessment tool.
We are currently undertaking a controlled trial of elec-
tronic order entry and a CDSS, which may also facilitate
appropriate prophylaxis. The effectiveness of these broader
strategies on patient and provider outcomes must be deter-
mined by further high-quality research.
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